<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asxannounc051024.txt
<TEXT>
UNITED STATES
SECURITIES	AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2005

Novogen Limited
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes   No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
	82- ________________	.1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 24 October, 2005  By /s/Ronald Lea Erratt Company Secretary

ASX & MEDIA RELEASE
24 OCTOBER, 2005

RESEARCHERS REPORT THAT PHENOXODIOL IS PRODUCING SIGNIFICANT
ANTI-CANCER RESPONSES IN WOMEN WITH GYNECOLOGICAL CANCERS

Novogen Limited's subsidiary, Marshall Edwards, Inc.
(LSE AIM: MSH and Nasdaq: MSHL) has just made the following
announcement to the London Stock Exchange's Alternative
Investment Market.

STAMFORD, Conn. October 24, 2005 - Researchers from Yale
University's School of Medicine have reported updated results
from two clinical studies they are conducting in women with
late-stage ovarian cancer and in women with early-stage cancer
of the cervix and vagina.

These data were presented on Saturday October 22, 2005 by
Yale researcher Dr Gil Mor at the International Menopause
Society Meeting in Buenos Aires, Argentina, and has been
claimed as a breakthrough in management of these highly
aggressive cancers by the use of the experimental
anti-cancer drug, phenoxodiol (PXD).

The ovarian cancer study involved 43 patients whose cancer
had failed to respond to all available therapies and were
regarded as being resistant or refractory to the standard
first-line therapies of a platinum (cisplatin or carboplatin)
and/or a taxane (paclitaxel). A primary purpose of the study
was to test the ability of PXD to reverse drug-resistance
to cisplatin or paclitaxel, thereby restoring the ability
of the cancers to respond to these potent anti-cancer drugs.

The key clinical endpoint of assessment of an experimental
oncology drug is the impact on survival.  Interim data
presented by Dr Mor indicated that after combining phenoxodiol
with either paclitaxel or cisplatin, overall survival has
been substantially extended.  The median survival in the
PXD plus cisplatin arm was 62 weeks and in the
PXD plus paclitaxel arm was 48 weeks.
At 75 weeks, 35% of patients in the PXD plus paclitaxel arm
were still alive and at 72 weeks, 35% of patients on the
PXD plus cisplatin arm were still alive.  This compares with
median survival reported for patients on standard therapy of
only 28 to 40 weeks.

Dr. Mor also reported that there was an improvement in disease
status by RECIST criteria in 45% of women receiving PXD plus
paclitaxel and in 58% of women receiving PXD plus cisplatin.
These responses included complete or partial tumor regression
in 10% and 29% of women in each group respectively and
stable disease in 35% and 29% respectively.

RECIST criteria require that patients can only be assigned
as being a responder or stable on the basis of 2 separate
radiological scans at least 4 weeks apart.  Since the trial
was conducted over a restricted treatment period of 3 months,
the number of women able to have a follow-up scan within that
period was restricted.  Some patients classified as showing
disease progression did show a response on one scan but because
they were not able to have a second scan within the trial period
could not be counted as either responder or stable.

In a separate trial, women with cervical cancer are being
treated with PXD alone as a first-line therapy for women with
recently diagnosed squamous cell carcinomas of the cervix,
vagina or vulva.  These cancers typically show very poor response
to chemotherapy, and normally are managed with surgery and
radiotherapy.  Preliminary data reported by Dr Mor at the
Buenos Aires meeting indicate that of 13 patients randomized
to two oral dose levels of 50 and 200 mg PXD given as a
monotherapy, 29% of patients produced a tumor response
(regression or stabilization of tumors) over a 4-week
period of treatment.

There were no PXD-related adverse events or side effects
reported in either study, indicating the high safety
profile of the drug.

Dr Mor said in his presentation that objective tumor
responses such as the complete and partial responses
that were seen here, especially in chemo-resistant ovarian
cancer patients, are very unusual, underlining the
chemo-sensitizing potential of phenoxodiol.

"A response with improved survival in this type of patients
demonstrates the uniqueness of this new drug when combined
with standard drug therapies," Dr Mor said.

"We are confident that these results indicate that phenoxodiol
demonstrates a promising new opportunity in the management
of these serious cancers experienced by many women" Dr Mor said.

According to data provided by the American Cancer Society,
ovarian cancer is the most lethal gynecological malignancy,
and 5th leading cause of cancer related death in women in
the USA.  Each year 25,400 new cases of ovarian cancer
are diagnosed in the US with 14,300 deaths annually
due to this disease.  As many as 1 in 70 women will develop
ovarian cancer and 1 in 100 women will die from this disease.
This high mortality is due mainly to the inability to detect
early disease, with approximately 80% of patients being diagnosed
in advanced-staged disease.  Even in those patients diagnosed
with early-stage disease, the 5-year survival rate ranges from
60 - 90% depending on the degree of tumor differentiation.
Despite treatment advances in the last 10 years no advances
have been made in overall survival.

Professor Graham Kelly, Chairman of Marshall Edwards, Inc.,
said "the data presented by Dr Mor is the type of outcome
that we are seeking to confirm with phenoxodiol in the
OVATURE study."

The OVATURE study is a multi-national Phase III pivotal study to
be conducted at up to 50 sites in the USA, Europe and Australia.
Patients with late-stage ovarian cancer that has become
refractory to at least 3 lines of platinum therapy are to
receive PXD and carboplatin in an attempt to restore
responsiveness to the carboplatin.

"The cervical cancer data also is highly interesting,"
Professor Kelly added, "providing evidence that
orally-administered PXD has a significant anti-tumor effect,
particularly in the case of squamous cell carcinomas,
which are relatively insensitive to standard anti-cancer drugs."

About Phenoxodiol
PXD is an investigational drug and, as such, is not marketed
in the United States.
PXD targets the plasma membrane sphingomyelin pathway,
inhibiting the production of the pro-survival secondary messenger,
sphingosine-1-phosphate (S-1-P), and in turn preventing
the phosphorylation of the Akt signalling cascade and the
formation of anti-apoptotic proteins.


PXD is highly selective, with no detectable effect on the
sphingomyelin pathway of non-tumor cells, accounting for the fact
that PXD has no augmenting effect on the toxic effects of
chemotoxic drugs on normal tissues.

Marshall Edwards, Inc., has licensed rights to bring phenoxodiol
to market globally from its parent company,
Novogen Limited. (ASX: Novogen - Nasdaq: NVGN).
Novogen is developing a range of therapeutics across
the fields of oncology, cardiovascular disease and
inflammatory diseases based on its phenolic drug technology
platform.

More information on phenoxodiol and on the Novogen group of
companies can be found at www.marshalledwardsinc.com
and www.novogen.com.


Under U.S. law, a new drug cannot be marketed until it has
been investigated in clinical trials.  After the results of
these trials are submitted in a new drug application to
the FDA, the FDA must approve the drug as safe and effective
before marketing can take place.

Statements included in this press release that are not
historical in nature are "forward-looking statements"
within the meaning of the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. You should
be aware that our actual results could differ materially from
those contained in the forward-looking statements, which are
based on management's current expectations and are subject
to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval,
of our product candidates; uncertainties in clinical trial
results; our inability to maintain or enter into, and
the risks resulting from our dependence upon, collaboration
or contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our
inability to protect our patents or proprietary rights
and obtain necessary rights to third party patents and
intellectual property to operate our business; our inability
to operate our business without infringing the patents and
proprietary rights of others; general economic conditions;
the failure of any products to gain market acceptance; our
inability to obtain any additional required financing;
technological changes; government regulation; changes in
industry practice; and one-time events. We do not intend to
update any of these factors or to publicly announce the
results of any revisions to these forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Novogen Limited, + 61.2.9878 0088
</TEXT>
</DOCUMENT>
